iBio(US:IBIO) Globenewswire·2025-10-30 11:00Core Insights - iBio, Inc. has announced promising preclinical data for IBIO-610, a potential first-in-class Activin E antibody, which shows an extended half-life in obese non-human primates and a predicted human half-life of up to 100 days, allowing for dosing as infrequently as twice a year [1][2][4] Group 1: Product Development - IBIO-610 demonstrates a half-life of 33.2 days in non-human primates, with projections indicating a human half-life of up to 100 days, which could significantly enhance patient experience by reducing dosing frequency to once every six months [1][2] - The antibody's mechanism of action is expected to provide a more comprehensive pathway modulation for obesity treatment compared to existing therapies [4] Group 2: Market Positioning - The CEO of iBio highlighted the need for durable treatment options beyond appetite control, emphasizing the potential of IBIO-610 to fill this gap in patient care [2] - The company’s AI-enabled discovery platform has successfully developed a long-acting antibody against Activin E, which could leverage the scalability of global antibody manufacturing [2] Group 3: Upcoming Presentation - The findings regarding IBIO-610 will be presented at ObesityWeek 2025, scheduled for November 4-7 in Atlanta, which may enhance visibility and interest in the product [1][2]